Cellivery Applies for FDA IND for Phase 1 Clinical Trial of COVID-19 Immune Therapy

[Asia Economy Reporter Minji Lee] Cellivery announced on the 13th that it has submitted an Investigational New Drug (IND) application for the Phase 1 clinical trial of the COVID-19 immune therapeutic iCP-NI to the U.S. Food and Drug Administration (FDA).

The company stated, "Based on non-clinical trial (safety evaluation) results, GLP-level toxicity tests of iCP-NI confirmed that effective drug concentrations are reached at low doses," adding, "We expect the development of a COVID-19 immune therapeutic that can demonstrate efficacy against various inflammatory diseases without causing toxicity."